View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 22, 2021

Synthetic doses subjects in Phase I trial of therapy for GI diseases

The multiple-ascending dose trial will assess the repeated doses of SYN-020 in up to 32 healthy adults.

Synthetic Biologics has initiated enrolment and dosed eight subjects in a Phase I clinical trial of SYN-020 intestinal alkaline phosphatase (IAP) to potentially prevent and treat gastrointestinal (GI) diseases.

Formulated for oral delivery to the small intestine, SYN-020 is a recombinant bovine IAP.

The ongoing, placebo-controlled, multiple-ascending dose (MAD) Phase I trial will assess the safety, tolerability and biodistribution of repeated doses of SYN-020 in up to 32 healthy adult subjects.

They will be categorised into four sequential arms of eight each to receive either oral twice-daily 5mg, 15mg, 45mg or 75mg doses of SYN-020 for 14 days.

Synthetic will conduct a safety analysis, on concluding each arm, to assess if advancing to higher doses is feasible.

Topline results from the trial are expected in the second quarter of next year.

A Phase I single-ascending dose (SAD) clinical trial of SYN-020 that enrolled 24 healthy adult subjects concluded recently.

These participants were categorised into four arms to receive single oral doses of SYN-020 ranging from 5mg to 150mg.

Initial data analyses showed that SYN-020 had a favourable safety profile and was well-tolerated at all tested doses in the trial.

Furthermore, no adverse events and serious adverse events linked to the treatment were reported.

Synthetic Biologics CEO and chief financial officer Steven Shallcross said: “We are excited to announce the initiation of the Phase I multiple-ascending dose clinical study, which is an important milestone in furthering the clinical development of SYN-020 for multiple potential indications.

“SYN-020 is a promising, versatile programme that we believe has enormous potential to help address a considerable need for innovative new therapies targeting disorders that stem from immune and inflammatory damage to the intestine, including celiac disease, non-alcoholic fatty liver disease (NAFLD), age-related metabolic and inflammatory diseases, and radiation enteropathy.”

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy